CC BY-NC-ND 4.0 · The Arab Journal of Interventional Radiology 2018; 02(03): S20
DOI: 10.1055/s-0041-1730698
Abstract

A Retrospective Comparative Study of Four Different Transarterial Regimens for Treatment of Hepatocellular Carcinoma

Abdulaziz Almat Hami
Western University, Ontario, Canada, Riyadh, Saudi Arabia
,
Hatim Alobaidi
Prince Sultan Military Medical City, Riyadh, Saudi Arabia
,
Yousof Alzahrani
King Abdulaziz Medical City, Riyadh, Saudi Arabia
,
Rebecca Zener
Western University, Ontario, Canada, Riyadh, Saudi Arabia
,
Daniele Wiseman
Western University, Ontario, Canada, Riyadh, Saudi Arabia
,
Amol Mujoomdar
Western University, Ontario, Canada, Riyadh, Saudi Arabia
› Author Affiliations

Background: Transarterial chemoembolization (TACE) is known to be a valid palliative measure in treating hepatocellular carcinoma (HCC). Indeed, it is considered as the first option in treating patients with unresectable multinodular HCC in the absence of portal vein thrombosis or invasion with preserved liver function. Furthermore, chemoembolization is also used as an adjuvant therapy to prevent tumor progression or to downstage the tumor to meet the transplantation criteria. Despite that, there is no standardized treatment regimen for chemoembolization. This single-center retrospective study aims to compare four different regimens of TACE for the treatment of unresectable HCC to assess tumor response, time to progression (TTP), and median survival. Methods: Ninety-eight TACE procedures on 88 patients with unresectable HCC (77 males and 11 females; mean age 68.4 years) performed between June 2007 and July 2014 were included. Four groups based on the regimen were compared. This includes 10 patients treated with I-131-lipiodol combined with cisplatin and doxorubicin (Group A), 15 patients treated with cisplatin and doxorubicin mixed with lipiodol (Group B), 53 patients treated with doxorubicin mixed with lipiodol (Group C), and 10 patients treated with doxorubicin-eluting beads (DEB-TACE) (Group D). The outcome measures reviewed were imaging response, TTP, technical success, and median survival. The tumor measurements were analyzed based on mRECIST criteria. Statistical analysis was performed using ANOVA and post hoc Tukey’s test. Results: There is no statistically significant difference in the baseline tumor size among the study groups (P = 0.67): (Group A: mean 7.9 cm, median 6.3 cm; Group B: mean 6.1 cm, median 5.6 cm; Group C: mean 6.2 cm, median 5.7 cm; and Group D: mean 6.0 cm, median 4.7 cm). A complete response to the treatment was slightly higher in Groups B and C (15% and 13%, respectively) compared to Groups A and D (10%). The median TTP was shorter in Group A (4 months) compared to (6 months) Groups B, C, and D. There is no significant difference in median survival among the study groups (P = 0.96). Conclusion: Based on our review, there is no significant difference in imaging response, TTP, and survival between single agent TACE, dual agent TACE, radio-chemoembolization with dual agents, and DEB-TACE.



Publication History

Article published online:
11 May 2021

© 2018. The Arab Journal of Interventional Radiology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India